Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials. [electronic resource]
Producer: 20180702ISSN:- 2047-9980
- Adolescent
- Adrenergic beta-Antagonists -- adverse effects
- Adult
- Aged
- Aldehyde Dehydrogenase 1 Family
- Angiotensin-Converting Enzyme Inhibitors -- therapeutic use
- Antihypertensive Agents -- adverse effects
- Atenolol -- adverse effects
- Blood Pressure -- drug effects
- Calcium Channel Blockers -- therapeutic use
- Chi-Square Distribution
- Drug Combinations
- Drug Resistance -- genetics
- Female
- Florida
- Genome-Wide Association Study
- Georgia
- Humans
- Hydrochlorothiazide -- adverse effects
- Hypertension -- diagnosis
- Indoles -- therapeutic use
- Logistic Models
- Male
- Middle Aged
- Multivariate Analysis
- Odds Ratio
- Pharmacogenetics
- Pharmacogenomic Variants
- Polymorphism, Single Nucleotide
- Prospective Studies
- Retinal Dehydrogenase -- genetics
- Risk Factors
- Sodium Chloride Symporter Inhibitors -- adverse effects
- Treatment Outcome
- Vasodilator Agents -- therapeutic use
- Verapamil -- therapeutic use
- Young Adult
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.